CEACAM5 and neoplasm: In an interim analysis of a first in-human study (NCT02187848) in patients with non-squamous NSCLC, SAR408701 showed an objective response rate (ORR) of only 23%, even in patients with ≥ 50% of CEACAM5-expressing tumor cells.